Going beyond HIPAA compliance is worthwhile
Just because HIPAA doesn’t require the use of data governance technology doesn’t mean you can do without it.
Healthcare staffing outlook: A more competitive market and higher rates of burnout
The healthcare industry has faced unprecedented staffing challenges over the past two years. Learn what the leaders of CHG Healthcare’s staffing brands had to say about the competition to attract and retain providers in 2022.
‘Interesting anomaly’: Hospital M&A fell to record low in Q1
Hospital M&A activity in the first quarter bucked last year’s trends as both the amount and size of deals shrank, according to Kaufman Hall.
Centene’s former longtime leader Michael Neidorff dies
Neidorff transformed the St. Louis-based insurer into a formidable player in the healthcare sector during his 26 years at the helm.
Medicare finalizes policy limiting coverage of Biogen Alzheimer’s drug
Treatment with Aduhelm would only be covered for patients enrolled in a clinical trial under the policy, which largely follows a draft proposal released in January.
FDA clarifies cybersecurity recommendations for device makers in new guidance
The draft guidance, which replaces a 2018 document, sets recommendations for how medical device companies should approach cybersecurity in premarket submissions.
FDA sees ‘appropriate’ transition period for COVID-19 test EUAs when public health emergency ends
FDA is planning to give holders of EUAs for COVID-19 diagnostics and other devices 180 days notice of its intent to terminate their authorizations, in anticipation of U.S. public health emergency declarations no longer being in effect.
Advocate Aurora investment arm acquires remote monitoring firm
This is the fourth transaction for the newly minted Advocate Aurora Enterprise, which launched last year with the aim of building a portfolio of companies beyond acute medical care.
FDA advisers grapple with how to update COVID-19 vaccines
About half of eligible Americans haven’t received a booster and may be less protected should cases surge. Health officials hope to soon ready an updated shot, but experts on the committee struggled to identify the best approach.
FDA halts Vir, GSK antibody use in response to COVID subvariant’s spread
The COVID-19 treatment had a brief time in the spotlight as one of the few drugs that’s potent against the omicron variant. A substrain called BA.2 is now dominant in the U.S., however.